San Francisco’s Thriving Comeback: Unleash Your Wealth Potential with These Must-Watch Stocks from the City by the Bay!
An aerial view captures the iconic Golden Gate Bridge with the San Francisco skyline in the background, as the city shows signs of resurgence. In a fitting move, CNBC recently broadcasted its “Power Lunch” segment from stunning studios in the heart of San Francisco, highlighting the city’s vibrant business landscape.
As part of the programming, I explored the most lucrative companies based in San Francisco, uncovering some surprising names. Despite expectations that artificial intelligence firms would dominate the list, it turned out that the biotechnology sector led the charge, showcasing the city’s diverse economic prospects.
To identify these noteworthy stocks, the “Power Lunch” team focused on companies headquartered in San Francisco proper, excluding those located in nearby Silicon Valley. The selection criteria filtered out businesses with market capitalizations below $500 million, ensuring only significant players remained. After applying these parameters, a screen via FactSet revealed a roster dominated by biotech firms.
Over the past three months, the standout performer has been Nektar Therapeutics (NKTR), which saw its stock soar by an impressive 158.65%. Nektar is advancing treatments for conditions such as dermatitis and alopecia areata, and analysts project a bullish average price target of $93.60 for the stock-indicating potential growth of nearly 50% from its current level.
Sunrun Inc. (RUN) secured the second spot, doubling in value within three months. Although the journey has been turbulent-witnessing fluctuations from $20 to $6 and back-CEO Mary Power is set to discuss the company’s trajectory live on “Power Lunch” this week.
Another major contender is The RealReal (REAL), a luxury resale platform aiming to monetize the closets of consumers by offering high-end fashion at discounted prices. Caution is advised, however, as the stock hovers just above the median price target offered by analysts.
Planet Labs (PL), classified as an “earth intelligence” company, rounds out the top performers. The company has nearly doubled its stock price in the past year as its sales have surged more than 100% over the last four years. However, investors should note that Planet Labs has also experienced significant volatility, with shares dropping to below $2 last year before rebounding.
Additional names worth mentioning include Fastly (FSLY), Maze Therapeutics (MAZE), Olema Pharmaceuticals (OLMA), and Cytokinetics (CYTK), all of which have enjoyed favorable performance in a market that is increasingly showing appreciation for biotech and medical companies dedicated to addressing significant health concerns.
Viewers tuning in to CNBC’s broadcast are often left captivated by the backdrop of the Bay and the Bay Bridge-an authentic scene that some might mistake for a digital creation. As the “Power Lunch” team continues its discussions with various CEOs from these standout companies, viewers can expect exclusive insights and interviews throughout the week, available on the Power Lunch page.
San Francisco’s financial prowess is evident in this surprising array of companies driving investor interest, underscoring the city’s resilience and its ability to yield profitable opportunities.
Categories: Business, Finance
Tags: San Francisco, Nektar Therapeutics, biotechnology, Power Lunch, CNBC, investments, stock market, economic resurgence
Original Source: https://www.cnbc.com/2025/10/28/san-francisco-is-making-a-comeback-so-are-these-stocks-from-the-city-by-the-bay.html
Category :
Tags:
Publish Date: 2025-10-28 23:28:00
